SCHEMBL3437174

SCHEMBL3437174

CC(=O)Oc1ccc(OC(C)=O)c(/C=C/C=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
LMNA P02545 4/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.44
CYP3A4 P08684 2/20 0.44
TTR P02766 1/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPK1 P28482 1/20 0.43
JUN P05412 1/20 0.42
NFKB1 P19838 1/20 0.42
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3437175 1.00 KDM4E (0.47) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL3437173 0.83 KDM4E (0.53) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL31074934 0.83 CYP1A1 (0.57) KDM4EKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL344620 0.81 AKR1C3 (0.52) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL344621 0.81 AKR1C3 (0.52) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL9320672 0.81 KDM4E (0.44) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL9320684 0.81 KDM4E (0.44) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL15330637 0.80 CDK4 (0.52) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL6475481 0.80 CDK4 (0.52) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL10412321 0.79 MTNR1A (0.47) KDM4ELMNAKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331549-A1 Novel compounds useful for modulating abnormal cell proliferation ROIFMAN CHAIM 2010-12-30 US disclosed
US-20100331549-A1 Novel compounds useful for modulating abnormal cell proliferation ROIFMAN CHAIM 2010-12-30 US disclosed
US-20100331549-A1 Novel compounds useful for modulating abnormal cell proliferation ROIFMAN CHAIM 2010-12-30 US disclosed
US-7807719-B2 Compounds useful for modulating abnormal cell proliferation Roifman, Chaim (CA) 2010-10-05 US disclosed
US-7807719-B2 Compounds useful for modulating abnormal cell proliferation Roifman, Chaim (CA) 2010-10-05 US disclosed
US-7807719-B2 Compounds useful for modulating abnormal cell proliferation Roifman, Chaim (CA) 2010-10-05 US disclosed
EP-1797064-A4 NOVEL COMPOUNDS USEFUL FOR MODULATING ABNORMAL CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2009-06-24 EP disclosed
EP-1797064-A1 NOVEL COMPOUNDS USEFUL FOR MODULATING ABNORMAL CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2007-06-20 EP disclosed
WO-2006029515-A1 NOVEL COMPOUNDS USEFUL FOR MODULATING ABNORMAL CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2006-03-23 WO disclosed
US-20060058297-A1 4-Chloro-2-cyano-5-phenyl-penta-2E,4Z-dienoic acid 3,4-dihydroxybenzylamide, used as antiproliferative agents THE HOSPITAL FOR SICK CHILDREN 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058297-A1 4-Chloro-2-cyano-5-phenyl-penta-2E,4Z-dienoic acid 3,4-dihydroxybenzylamide, used as antiproliferative agents MKI67, CCNA2, CDK4 KDM4E 279/4885LMNA 1323/4885KMT2A 1519/4885
US-20100331549-A1 Novel compounds useful for modulating abnormal cell proliferation MKI67, CALU, CDK4 KDM4E 3729/4885LMNA 2586/4885KMT2A 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.